The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review (original) (raw)

Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Archives of General Psychiatry, 2007

Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)

Michael Davidson

American Journal of Psychiatry, 2009

View PDFchevron_right

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

Jiří Horáček

CNS Drugs, 2006

View PDFchevron_right

Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients

Isabell Heuser

Schizophrenia Research, 2010

View PDFchevron_right

Antipsychotic Medication for Early-Episode Schizophrenia

John Bola

Schizophrenia Bulletin, 2011

View PDFchevron_right

Effectiveness of clozapine in treatment-resistant schizophrenia

Raguraman Janakiraman

Indian Journal of Psychiatry, 2005

View PDFchevron_right

ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder

Jason Noel

American Journal of Health-system Pharmacy, 2020

View PDFchevron_right

Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia

Robert Rosenheck

New England Journal of Medicine, 2011

View PDFchevron_right

Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics

Takefumi Suzuki

Journal of Clinical Psychopharmacology, 2018

View PDFchevron_right

Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia

Alison Markwick

Schizophrenia Bulletin, 2005

View PDFchevron_right

Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients

Eva Peñas Lledó

European Journal of Clinical Pharmacology, 2007

View PDFchevron_right

Cytokines in schizophrenia and the effects of antipsychotic drugs

Ewa Obuchowicz

Brain Behavior and Immunity, 2006

View PDFchevron_right

Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View

Arsime Demjaha

Frontiers in Psychiatry, 2019

View PDFchevron_right

Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness

Gretchen Haas

Journal of Psychiatric Research, 1998

View PDFchevron_right

cognitive impairment in patients with schizophrenia a hospital based cross sectional study

ADITI JAIN

View PDFchevron_right

Adverse Drug Reactions Affiliated with Atypical Antipsychotics in Patients with Schizophrenia

shweta oommen

Journal of Young Pharmacists, 2019

View PDFchevron_right

The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis

Luke Vano

Molecular Psychiatry, 2019

View PDFchevron_right

Schizophrenia: from neurophysiological abnormalities to clinical symptoms

Fabio Ferrarelli

Frontiers in Psychology, 2015

View PDFchevron_right

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East

Nasser Al Zain

Neuropsychiatric Disease and Treatment, 2015

View PDFchevron_right

Elke Schnur

Schizophrenia Research, 2000

View PDFchevron_right

Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults

Lissette Saavedra

2012

View PDFchevron_right

Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction

Stephen Faraone

Biological Psychiatry, 1993

View PDFchevron_right

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia

Jari Tiihonen

JAMA Psychiatry, 2019

View PDFchevron_right

The Neurobiology of Schizophrenia

Martin Franetič

View PDFchevron_right

Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach

Robert Rosenheck

Psychiatric Quarterly, 2014

View PDFchevron_right

Neurological Adverse Effects of Antipsychotics in Children and Adolescents

cecilia tapia

Journal of Clinical Psychopharmacology, 2015

View PDFchevron_right

Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data

Anatoly Kreinin

View PDFchevron_right

Predictors of antipsychotic dose changes in the CATIE schizophrenia trial

Robert Rosenheck

Psychiatry Research, 2012

View PDFchevron_right

Pharmacological Treatment of Schizophrenia and Co-Occurring Substance Use Disorders

Noosha Niv

CNS Drugs, 2008

View PDFchevron_right

A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia

mohammad reza khodaie

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008

View PDFchevron_right

Cognitive Functions and Medication Compliance in relation to Quality of Life in Persons with Schizophrenia

Manoj K U M A R Bajaj

International Journal of Indian Psychology, 2018

View PDFchevron_right

Pharmacology of atypicality of antipsychotic drugs: status and perspectives

Adrian Newman-Tancredi

Archives of Psychiatry and …, 2010

View PDFchevron_right

Clozapine versus other atypical antipsychotics for schizophrenia

Claudia Asenjo-Lobos

Cochrane Database of Systematic Reviews, 2010

View PDFchevron_right

In Response to "The neuroleptic treatment of schizophrenia: dosing strategies, depot preparations and novel medications" by Alexander S. Young, M.D. (volume 13, 18-26)

Joseph Cassar

Jefferson Journal of Psychiatry, 1998

View PDFchevron_right

The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review (original) (raw)

Related papers